123 related articles for article (PubMed ID: 22979950)
21. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
[TBL] [Abstract][Full Text] [Related]
22. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.
Varsani A; Williamson AL; de Villiers D; Becker I; Christensen ND; Rybicki EP
J Virol; 2003 Aug; 77(15):8386-93. PubMed ID: 12857908
[TBL] [Abstract][Full Text] [Related]
23. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6.
Christensen ND; Reed CA; Cladel NM; Hall K; Leiserowitz GS
Virology; 1996 Oct; 224(2):477-86. PubMed ID: 8874508
[TBL] [Abstract][Full Text] [Related]
24. Immunization with Human Papillomavirus 16 L1+E2 Chimeric Capsomers Elicits Cellular Immune Response and Antitumor Activity in a Mouse Model.
López-Toledo G; Schädlich L; Alonso-Castro ÁJ; Monroy-García A; García-Rocha R; Guido MC; Gissmann L; García-Carrancá A
Viral Immunol; 2016 Jun; 29(5):276-87. PubMed ID: 27058179
[TBL] [Abstract][Full Text] [Related]
25. Expression of HPV6b L1/EBV LMP2 multiepitope and immunogenicity in mice.
Zhu S; Xue X; Liu J; Lu L; Zhao P; Wang J; Li W; Zhang L
Acta Biochim Biophys Sin (Shanghai); 2010 Aug; 42(8):515-21. PubMed ID: 20705592
[TBL] [Abstract][Full Text] [Related]
26. Analysis of CD4(+) T-cell responses to human papillomavirus (HPV) type 11 L1 in healthy adults reveals a high degree of responsiveness and cross-reactivity with other HPV types.
Williams OM; Hart KW; Wang EC; Gelder CM
J Virol; 2002 Aug; 76(15):7418-29. PubMed ID: 12097554
[TBL] [Abstract][Full Text] [Related]
27. A Dual-Type L2 11-88 Peptide from HPV Types 16/18 Formulated in Montanide ISA 720 Induced Strong and Balanced Th1/Th2 Immune Responses, Associated with High Titers of Broad Spectrum Cross-Reactive Antibodies in Vaccinated Mice.
Motavalli Khiavi F; Arashkia A; Golkar M; Nasimi M; Roohvand F; Azadmanesh K
J Immunol Res; 2018; 2018():9464186. PubMed ID: 29854852
[No Abstract] [Full Text] [Related]
28. Antigenic presentation of heterologous epitopes engineered into the outer surface-exposed helix 4 loop region of human papillomavirus L1 capsomeres.
Murata Y; Lightfoote PM; Rose RC; Walsh EE
Virol J; 2009 Jun; 6():81. PubMed ID: 19538743
[TBL] [Abstract][Full Text] [Related]
29. Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31.
Fleury MJ; Touzé A; Alvarez E; Carpentier G; Clavel C; Vautherot JF; Coursaget P
Arch Virol; 2006 Aug; 151(8):1511-23. PubMed ID: 16508703
[TBL] [Abstract][Full Text] [Related]
30. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.
Monroy-García A; Gómez-Lim MA; Weiss-Steider B; Hernández-Montes J; Huerta-Yepez S; Rangel-Santiago JF; Santiago-Osorio E; Mora García Mde L
Arch Virol; 2014 Feb; 159(2):291-305. PubMed ID: 23990055
[TBL] [Abstract][Full Text] [Related]
31. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND
Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603
[TBL] [Abstract][Full Text] [Related]
32. Type-specific and cross-reactive antibodies induced by human papillomavirus 31 L1/L2 virus-like particles.
Xu Y; Wang Q; Han Y; Song G; Xu X
J Med Microbiol; 2007 Jul; 56(Pt 7):907-913. PubMed ID: 17577054
[TBL] [Abstract][Full Text] [Related]
33. Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer.
Baek JO; Seo JW; Kwon O; Park SM; Kim CH; Kim IH
Enzyme Microb Technol; 2012 Mar; 50(3):173-80. PubMed ID: 22305172
[TBL] [Abstract][Full Text] [Related]
34. Identification of the murine H-2D(b) and human HLA-A*0201 MHC class I-restricted HPV6 E7-specific cytotoxic T lymphocyte epitopes.
Peng S; Mattox A; Best SR; Barbu AM; Burns JA; Akpeng B; Jeang J; Yang B; Ishida E; Hung CF; Wu TC; Pai SI
Cancer Immunol Immunother; 2016 Mar; 65(3):261-71. PubMed ID: 26759151
[TBL] [Abstract][Full Text] [Related]
35. Co-vaccination with adeno-associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM-CSF can elicit strong and prolonged neutralizing antibody.
Liu DW; Chang JL; Tsao YP; Huang CW; Kuo SW; Chen SL
Int J Cancer; 2005 Jan; 113(1):93-100. PubMed ID: 15386434
[TBL] [Abstract][Full Text] [Related]
36. Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies.
Combelas N; Saussereau E; Fleury MJ; Ribeiro T; Gaitan J; Duarte-Forero DF; Coursaget P; Touzé A
J Transl Med; 2010 Mar; 8():28. PubMed ID: 20334659
[TBL] [Abstract][Full Text] [Related]
37. Type specific and genotype cross reactive B epitopes of the L1 protein of HPV16 defined by a panel of monoclonal antibodies.
Kulski JK; Sadleir JW; Kelsall SR; Cicchini MS; Shellam G; Peng SW; Qi YM; Galloway DA; Zhou J; Frazer IH
Virology; 1998 Apr; 243(2):275-82. PubMed ID: 9568027
[TBL] [Abstract][Full Text] [Related]
38. Characterization of a major neutralizing epitope on human papillomavirus type 16 L1.
White WI; Wilson SD; Palmer-Hill FJ; Woods RM; Ghim SJ; Hewitt LA; Goldman DM; Burke SJ; Jenson AB; Koenig S; Suzich JA
J Virol; 1999 Jun; 73(6):4882-9. PubMed ID: 10233949
[TBL] [Abstract][Full Text] [Related]
39. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes.
van der Burg SH; Ressing ME; Kwappenberg KM; de Jong A; Straathof K; de Jong J; Geluk A; van Meijgaarden KE; Franken KL; Ottenhoff TH; Fleuren GJ; Kenter G; Melief CJ; Offringa R
Int J Cancer; 2001 Mar; 91(5):612-8. PubMed ID: 11267969
[TBL] [Abstract][Full Text] [Related]
40. Purification and immunogenicity study of human papillomavirus type 16 L1 protein in Saccharomyces cerevisiae.
Kim SN; Jeong HS; Park SN; Kim HJ
J Virol Methods; 2007 Jan; 139(1):24-30. PubMed ID: 17034867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]